The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study
Open accessAbstract
Background Vaccine effectiveness studies have not differentiated the effect of the delta (B.1.617.2) variant and potential waning immunity in observed reductions in effectiveness against SARS-CoV-2 infections. We aimed to evaluate overall and variant-specific effectiveness of BNT162b2 (tozinameran, Pfizer-BioNTech) against SARS-CoV-2 infections and COVID-19-related hospital admissions by time since vaccination among members of a large US health-care system. Methods In this retrospective cohort study, we analysed electronic health records of individuals (≥12 years) who were members of the health-care organisation Kaiser Permanente Southern California (CA, USA), to assess BNT162b2 vaccine effectiveness against SARS-CoV-2 infections and COVID-19-related hospital admissions for up to 6 months. Participants were required to have 1 year or more previous membership of the organisation. Outcomes comprised SARS-CoV-2 PCR-positive tests and COVID-19-related hospital admissions. Effectiveness calculations were based on hazard ratios from adjusted Cox models. This study was registered with ClinicalTrials.gov, NCT04848584. Findings Between Dec 14, 2020, and Aug 8, 2021, of 4 920 549 individuals assessed for eligibility, we included 3 436 957 (median age 45 years [IQR 29-61]; 1 799 395 [52·4%] female and 1 637 394 [47·6%] male). For fully vaccinated individuals, effectiveness against SARS-CoV-2 infections was 73% (95% CI 72-74) and against COVID-19-related hospital admissions was 90% (89-92). Effectiveness against infections declined from 88% (95% CI 86-89) during the first month after full vaccination to 47% (43-51) after 5 months. Among sequenced infections, vaccine effectiveness against infections of the delta variant was high during the first month after full vaccination (93% [95% CI 85-97]) but declined to 53% [39-65] after 4 months. Effectiveness against other (non-delta) variants the first month after full vaccination was also high at 97% (95% CI 95-99), but waned to 67% (45-80) at 4-5 months. Vaccine effectiveness against hospital admissions for infections with the delta variant for all ages was high overall (93% [95% CI 84-96]) up to 6 months. Interpretation Our results provide support for high effectiveness of BNT162b2 against hospital admissions up until around 6 months after being fully vaccinated, even in the face of widespread dissemination of the delta variant. Reduction in vaccine effectiveness against SARS-CoV-2 infections over time is probably primarily due to waning immunity with time rather than the delta variant escaping vaccine protection. Funding Pfizer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Several studies have described a drop over time of two-dose vaccine effectiveness against SARS-CoV-2 symptomatic infection;”
From Vaccine effectiveness and duration of protection of COVID-19 mRNA vaccines against Delta and Omicron BA.1 symptomatic and severe COVID-19 outcomes in adults aged 50 years and over in France (2023) · cites this paper as [8]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“this decrease in protection was substantially higher against Omicron BA.1 compared to Delta [3,8,12,19,26].”
From Vaccine effectiveness and duration of protection of COVID-19 mRNA vaccines against Delta and Omicron BA.1 symptomatic and severe COVID-19 outcomes in adults aged 50 years and over in France (2023) · cites this paper as [8]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Real-world setting studies performed, few months into vaccination campaigns, showed high effectiveness of these vaccines [1-8].”
The cited source says what the claim attributes to it.
In the citing paper
“However, as vaccination campaigns progressed, additional vaccine effectiveness (VE) studies revealed waning of the vaccine-induced protection over time [8-13]”
In the citing paper
“Yet, vaccine-induced immunity remains effective at preventing severe disease, hospitalization, and death, even at later time points when antibody levels may have declined (10–12).”
From mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern (2021) · cites this paper as [10]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592
Khoury, D. S., Cromer, D., Reynaldi, A., Schlub, T. E., Wheatley, A. K., Juno, J. A., Subbarao, K., Kent, S. J., Triccas, J. A., & Davenport, M. P. (2021) · Nature Medicine · doi:10.1038/s41591-021-01377-8 · Cited by 3,742
Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant
Lopez Bernal, J., Andrews, N., Gower, C., Gallagher, E., Simmons, R., Thelwall, S., Stowe, J., Tessier, E., Groves, N., Dabrera, G., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2108891 · Cited by 2,889
BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting
Dagan, N., Barda, N., Kepten, E., Miron, O., Perchik, S., Katz, M. A., Hernán, M. A., Lipsitch, M., Reis, B., & Balicer, R. D. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2101765 · Cited by 2,527
Six Month Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine
Thomas, S. J., Moreira, E. D., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Polack, F. P., Zerbini, C., et al. (2021) · doi:10.1101/2021.07.28.21261159 · Cited by 1,640
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months
Thomas, S. J., Moreira, E. D., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Polack, F. P., Zerbini, C., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2110345 · Cited by 1,640
Haas, E. J., Angulo, F. J., McLaughlin, J. M., Anis, E., Singer, S. R., Khan, F., Brooks, N., Smaja, M., Mircus, G., Pan, K., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00947-8 · Cited by 1,564
Self-citationLopez Bernal, J., Andrews, N., Gower, C., Robertson, C., Stowe, J., Tessier, E., Simmons, R., Cottrell, S., Roberts, R., O’Doherty, M., et al. (2021) · BMJ · doi:10.1136/bmj.n1088 · Cited by 1,389
The Development of a Standardized Neighborhood Deprivation Index
Messer, L. C., Laraia, B. A., Kaufman, J. S., Eyster, J. T., Holzman, C., Culhane, J. F., Elo, I. T., Burke, J. G., & O'Campo, P. J. (2006) · Journal of Urban Health · doi:10.1007/s11524-006-9094-x · Cited by 1,046
Sheikh, A., McMenamin, J., Taylor, B., & Robertson, C. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01358-1 · Cited by 939
Research works printed but not linked: 1
- Lopez Bernal, 2021, Effectiveness of Covid-19 vaccines against the B.1.617.2 (delta) variant, N Engl J Med, 385, 585, 10.1056/NEJMoa2108891 · DOI · Paper page
Cited by
Sorted by citations
Items 801–900 of 1,001
Efficacy Increase of Lipid Nanoparticles In Vivo by Inclusion of Bis(Monoacylglycerol)Phosphate
Sagi, A., Mukthavaram, R., Recatto, R., Hong, H., Davis, M., Dı́az-Trelles, R., El-Mecharrafie, N., Acharya, G., Gomez, A., Leu, A. I., et al. (2022) · Nanomedicine · doi:10.2217/nnm-2022-0002 · Cited by 2
Vaccine stockpile sharing for selfish objectives
Shivam, S., Weitz, J. S., & Wardi, Y. (2022) · PLOS Global Public Health · doi:10.1371/journal.pgph.0001312 · Cited by 2
Anti-SARS-Cov-2 S-RBD IgG Formed after BNT162b2 Vaccination Can Bind C1q and Activate Complement
Abu-Humaidan, A. H. A., Ahmad, F. M., Awajan, D., Jarrar, R. F., & Alaridah, N. (2022) · Journal of Immunology Research · doi:10.1155/2022/7263740 · Cited by 2
Lee, W., & Kurien, P. A. (2022) · Journal of Immunological Methods · doi:10.1016/j.jim.2022.113410 · Cited by 2
Adams, J. W., Jones, K., Preiss, S., Hadley, E., & Segelman, M. (2023) · Journal of Applied Gerontology · doi:10.1177/07334648231155873 · Cited by 2
SARS-CoV-2 Variant-Specific mRNA Vaccine: Pros and Cons
Shahsavandi, S., & Hariri, A. A. (2023) · Viral Immunology · doi:10.1089/vim.2022.0121 · Cited by 2
Yang, L., Xu, L., Guo, Q., Deng, B., Hong, Y., Wang, L., Wang, Y., Jiang, D., & Ren, H. (2023) · International Journal of Medical Sciences · doi:10.7150/ijms.78766 · Cited by 3
Cage, S. A., Warner, B. J., Gallegos, D. M., Cage, H., & Brown, D. (2022) · Internet Journal of Allied Health Sciences and Practice · doi:10.46743/1540-580x/2022.2180 · Cited by 2
New Trends and Challenges in Open Data
Kakulapati, V. (2023) · IntechOpen eBooks · doi:10.5772/intechopen.1000267 · Cited by 2
Behçet's patients' response to COVID-19 vaccination
Gokani, B., Sacoor, S., Leisegang, G. R., Ogunkolade, W. B., Bibi, A., Grigoriadou, S., Pade, C., Gibbons, J. M., Senusi, A. A., & Fortune, F. (2023) · Clinical Immunology · doi:10.1016/j.clim.2023.109700 · Cited by 2
Mahmoud, M. A., Ibrahim, A. A. M., Alharbi, F., Alalawi, A. M., Alnezary, F. S., Aldafiri, A., Alahmadi, Y. M., Alolayan, S. O., Althaqfan, S. S., Alsultan, M. M., et al. (2023) · Risk Management and Healthcare Policy · doi:10.2147/rmhp.s418300 · Cited by 2
Efficacy of COVID-19 Vaccines against the Omicron Variant of SARS-CoV-2: A Review
Rajsri, K. S., Singh, M., & Rao, M. (2023) · Exploratory Research and Hypothesis in Medicine · doi:10.14218/erhm.2023.00023 · Cited by 2
İskender, G., Mert, D., Toros, G. Y., YILMAZ, F., Bozan, E., Tunçbilek, S., Öksüzoğlu, B. Ç., Altuntaş, F., & Ertek, M. (2023) · TURKISH JOURNAL OF MEDICAL SCIENCES · doi:10.55730/1300-0144.5744 · Cited by 2
Matula, Z., Bekő, G., Király, V., Gönczi, M., Zóka, A., Baráth, A., Uher, F., & Valyi-Nagy, I. T. (2023) · Vaccines · doi:10.3390/vaccines12010003 · Cited by 2
International scientific communication on COVID-19 data: management pitfalls understanding
Tzivian, L., Benis, A., Rusakova, A., Syundyukov, E., Seidmann, A. A., & Ophir, Y. (2023) · Journal of Public Health · doi:10.1093/pubmed/fdad277 · Cited by 2
Ozawa, T., Ikeda, Y., Chen, L., Suzuki, R., Hoshino, A., Noguchi, A., Kita, S., Anraku, Y., Igarashi, E., Saga, Y., et al. (2024) · Structure · doi:10.1016/j.str.2023.12.013 · Cited by 2
The causal effect of a health treatment on beliefs, stated preferences and memories
Prati, A., & Saucet, C. (2024) · Journal of Health Economics · doi:10.1016/j.jhealeco.2024.102864 · Cited by 2
Surname order and revaccination intentions during the COVID-19 pandemic
Yamamura, E., Tsutsui, Y., & Ohtake, F. (2024) · Scientific Reports · doi:10.1038/s41598-024-55543-2 · Cited by 2
SARS-CoV-2 Vaccine-Elicited Immunity after B Cell Depletion in Multiple Sclerosis
Baxter, R. M., Cabrera-Martinez, B., Ghosh, T., Rester, C., Moreno, M. G., Borko, T. L., Selva, S., Fleischer, C. L., Haakonsen, N., Mayher, A., et al. (2024) · ImmunoHorizons · doi:10.4049/immunohorizons.2300108 · Cited by 2
Chiwandire, N., Walaza, S., von Gottberg, A., Wolter, N., du Plessis, M., Moosa, F., Groome, M. J., Nel, J. S., Variava, E., Dawood, H., et al. (2024) · International Journal of Epidemiology · doi:10.1093/ije/dyae116 · Cited by 3
Nakatani, E., Morioka, H., Kikuchi, T., & Fukushima, M. (2024) · Cureus · doi:10.7759/cureus.75652 · Cited by 3
Coronaviruses: Pandemic SARS-CoV-2
Cowling, B. J., & Wong, S. (2024) · Springer eBooks · doi:10.1007/978-1-4939-9544-8_68-1 · Cited by 2
Kamil, Q., Putri, W., Ayulinda, A. P., Maelani, I., Anwar, S., Ichsan, I., Pranata, A., Mudatsir, M., Syukri, M., Rizal, S., et al. (2024) · Narra J · doi:10.52225/narra.v4i3.788 · Cited by 3
Skrami, E., Faragalli, A., Iommi, M., Morbidoni, M., Mancini, C., Guidi, A., Cardone, A., Pompili, M., Serafini, P., Appignanesi, R., et al. (2025) · Scientific Reports · doi:10.1038/s41598-024-84100-0 · Cited by 3
Rethinking Optimal Immunogens to Face SARS‐CoV‐2 Evolution Through Vaccination
Blanco, J., Trinité, B., & Puig‐Barberà, J. (2025) · Influenza and Other Respiratory Viruses · doi:10.1111/irv.70076 · Cited by 2
Abbad, A., Yueh, J., Yellin, T., Singh, G., Carreño, J. M., Clark, J. J., Muramatsu, H., Tiwari, S., Bhavsar, D., Alzua, G. P., et al. (2024) · Vaccine · doi:10.1016/j.vaccine.2025.126825 · Cited by 2
Chun, K., Lee, C. J., Park, H., Jeong, W., Seo, K., Seo, J., Oh, J., Kim, H., Jang, J., Lee, H., et al. (2025) · Korean Circulation Journal · doi:10.4070/kcj.2024.0429 · Cited by 2
Humphreys, J., Nicolay, N., Braeye, T., Evercooren, I. V., Hansen, C. H., Moustsen‐Helms, I. R., Sacco, C., Mateo‐Urdiales, A., Castilla, J., Martínez‐Baz, I., et al. (2025) · BMC Medical Research Methodology · doi:10.1186/s12874-025-02742-8 · Cited by 2
Nagarajan, P., Vetrivel, A., Kumar, J., Howlader, A., Rangarajalu, K., Sabapathy, S. K., Gopal, M., & Kumar, S. (2022) · Journal of Mind and Medical Sciences · doi:10.22543/2392-7674.1343 · Cited by 2
Jaber, S. A., & Saadh, M. (2023) · Pharmacia · doi:10.3897/pharmacia.70.e97777 · Cited by 2
Design and Immunogenicity of SARS-CoV-2 DNA Vaccine Encoding RBD-PVXCP Fusion Protein
Dormeshkin, D., Katsin, M., Stegantseva, M. V., Golenchenko, S., Shapira, M. A., Dubovik, S., Lutskovich, D. V., Kavaleuski, A., & Meleshko, A. (2023) · Vaccines · doi:10.3390/vaccines11061014 · Cited by 3
Fu, Q., Xie, H., Zhou, L., Li, X., Liu, Y., Liu, M., Wang, C., Wang, X., Wang, Z., Tang, J., et al. (2021) · Trials · doi:10.1186/s13063-021-05837-x · Cited by 2
COVID Booster Shots: The Need of the Hour
Maheshwari, M., & Athiraman, H. (2021) · Cureus · doi:10.7759/cureus.19874 · Cited by 2
Zhang, G., Kuang, S., & Zhang, X. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2031453 · Cited by 3
Assessment of COVID-19 vaccination effectiveness
Stoczyńska-Fidelus, E., & Rieske, P. (2022) · Alergologia Polska - Polish Journal of Allergology · doi:10.5114/pja.2022.114393 · Cited by 2
Durability analysis of the highly effective mRNA-1273 vaccine against COVID-19
Puranik, A., Lenehan, P. J., O’Horo, J. C., Pawlowski, C., Virk, A., Swift, M. D., Kremers, W. K., Venkatakrishnan, A., Challener, D. W., Breeher, L. E., et al. (2022) · PNAS Nexus · doi:10.1093/pnasnexus/pgac058 · Cited by 2
Gibson, J. K. (2022) · New Zealand Economic Papers · doi:10.1080/00779954.2022.2077812 · Cited by 2
Alahmad, A., Kamel, S. A., Alsulimani, S. T., Alharbi, M. S., Alyazidi, F., & Allhaybi, Y. A. (2022) · Cureus · doi:10.7759/cureus.26016 · Cited by 2
Ogden, N. H., Turgeon, P., Fazil, A., Clark, J., Gabriele-Rivet, V., Tam, T. W. S., & Ng, V. (2022) · Relevé des maladies transmissibles au Canada · doi:10.14745/ccdr.v48i78a01f · Cited by 2
Patón, M., Hosani, F. I. A., Stanciole, A. E., Aden, B., Timoshkin, A., Sadani, A., Najim, O., Cherian, C. A., Acuna, J. M., & Rodríguez, J. (2022) · Infectious Disease Modelling · doi:10.1016/j.idm.2022.08.003 · Cited by 3
COVID-19 in patients with B cell immune deficiency
Vergidis, P. I., Levy, E. R., Ristagno, E. H., Iyer, V., O’Horo, J. C., & Joshi, A. Y. (2022) · Journal of Immunological Methods · doi:10.1016/j.jim.2022.113351 · Cited by 2
Whitley, C. S., & Mitchell, T. C. (2022) · Journal of Biological Methods · doi:10.14440/jbm.2022.390 · Cited by 2
IMPAK PANDEMIK COVID-19 TERHADAP PERTUMBUHAN DAN DAYA TAHAN POPULASI DI MALAYSIA
Mustafa, A. R., & Razli, A. Y. (2022) · International Journal of Interdisciplinary and Strategic Studies · doi:10.47548/ijistra.2022.61 · Cited by 2
Effectiveness of the Booster of SARS-CoV-2 Vaccine among Japanese Adolescents: A Cohort Study
Saito, Y., Yamamoto, K., Takita, M., Kami, M., Tsubokura, M., & Shibuya, K. (2022) · Vaccines · doi:10.3390/vaccines10111914 · Cited by 2
Insight into SARS-CoV-2 Omicron variants in Saudi Arabian genomic isolates
Darwish, D. B. E. (2022) · Saudi Medical Journal · doi:10.15537/smj.2022.43.11.20220381 · Cited by 2
Leuning, D. G., Groeneveld, G. H., Appelman, B., Wiersinga, W. J., & de Boer, M. G. J. (2022) · New Microbes and New Infections · doi:10.1016/j.nmni.2022.101047 · Cited by 2
Murata, G. H., Murata, A. E., Perkins, D. J., Campbell, H. M., Mao, J. T., Wagner, B., McMahon, B. H., & Hagedorn, C. H. (2022) · BMJ Open · doi:10.1136/bmjopen-2022-064135 · Cited by 2
Reynolds, J. A., Faustini, S. E., Tosounidou, S., Plant, T. D., Ubhi, M., Gilman, R., Richter, A. G., & Gordon, C. (2023) · Lupus · doi:10.1177/09612033231151603 · Cited by 2
Wilson, W. W., Keaton, A. A., Ochoa, L. G., Hatfield, K. M., Gable, P., Walblay, K., Teran, R. A., Shea, M., Khan, U., Stringer, G., et al. (2023) · Infection Control and Hospital Epidemiology · doi:10.1017/ice.2022.123 · Cited by 2
Combined Impact of Omicron Vaccination and Environmental Risk Exposure: A Thailand Case Study
Ounsaneha, W., Laosee, O. C., Suksaroj, T. T., & Rattanapan, C. (2023) · Vaccines · doi:10.3390/vaccines11020297 · Cited by 2
Zhao, D., Wang, X., Liu, J., Chinnappa, A. U., Basavaraj, V., Sri, C. D., Nikolenko, V. N., Beeraka, N. M., Shivaprakash, P., & Fan, R. (2023) · Current Pharmaceutical Biotechnology · doi:10.2174/1389201024666230227115329 · Cited by 2
González-Sánchez, Ó. A., González-Ortiz, L. J., Sánchez-Peña, M. J., Pulido, H. G., Cervantes, O., Márquez‐Sandoval, F., Hernández‐Bello, J., Casillas, N., & Muñóz-Valle, J. F. (2023) · Vaccines · doi:10.3390/vaccines11040719 · Cited by 2
Rajasi, R. S., Chandran, P., Sivakumar, C., George, B., Amrutha, D., Elizabeth, M., & George, A. M. (2023) · Journal of Family Medicine and Primary Care · doi:10.4103/jfmpc.jfmpc_1725_22 · Cited by 2
Xu, S., Hong, V. X., Sy, L. S., Bruxvoort, K. J., Lewin, B. J., Han, B., Holmquist, K. J., & Qian, L. (2023) · JMIR Public Health and Surveillance · doi:10.2196/46318 · Cited by 2
Self-citationPaduano, S., Facchini, M. C., Borsari, L., D’Alterio, A., Iacuzio, L., Greco, A., Fioretti, E., Creola, G., Kahfian, Z., Zona, S., et al. (2023) · Frontiers in Public Health · doi:10.3389/fpubh.2023.1240315 · Cited by 2
Hospitalisations and Deaths Averted by COVID-19 Vaccination in Navarre, Spain, 2021–2022
Martínez‐Baz, I., Trobajo‐Sanmartín, C., Miqueleiz, A., Egüés, N., Cenoz, M. G., Casado, I., Navascués, A., Fernández-Huerta, M., Echeverría, A., Guevara, M., et al. (2024) · Vaccines · doi:10.3390/vaccines12010058 · Cited by 3
Wu, G., Zhang, W., Wu, W., Wang, P., Huang, Z., Wu, Y., Li, J., Zhang, W., Du, Z., & Hao, Y. (2024) · Frontiers in Public Health · doi:10.3389/fpubh.2024.1343950 · Cited by 2
Is youTube effective on covid-19 vaccination during pregnancy
Doğru, Ş., Akkuş, F., & ATCI, A. A. (2022) · JOURNAL OF BIOTECHNOLOGY AND STRATEGIC HEALTH RESEARCH · doi:10.34084/bshr.1053290 · Cited by 2
Matsunami, M., Suzuki, T., Sugihara, S., Toishi, T., Nagaoka, K., Fukuda, J., Ohara, M., Takanashi, Y., Ochi, A., Yashima, J., et al. (2022) · Transplantation Proceedings · doi:10.1016/j.transproceed.2022.05.002 · Cited by 2
Šmíd, M., Berec, L., & Trnka, J. (2022) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiac259 · Cited by 2
BNT162b2 mRNA Vaccine–Induced Immune Response in Oral Fluids and Serum
Seneviratne, C. J., Balan, P., de Alwis, R., Udawatte, N. S., Herath, T., Toh, J. Z. N., Tin, G. B., Ooi, E. E., Hong, J. L. G., & Ying, J. S. X. (2022) · International Dental Journal · doi:10.1016/j.identj.2022.09.005 · Cited by 2
High COVID-19 vaccine coverage allows for a re-opening of European universitiesPreprint
Lasser, J., Hell, T., & García, D. (2021) · medRxiv · doi:10.1101/2021.11.16.21266383 · Cited by 2
Robles-Fontán, M. M., & Irizarry, R. A. (2021) · medRxiv · doi:10.1101/2021.12.19.21268070 · Cited by 2
Sajadi, M. M., Myers, A., Logue, J., Saadat, S., Shokatpour, N., Quinn, J., Newman, M., Deming, M., Tehrani, Z. R., Karimi, M., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.12.13.472159 · Cited by 2
Kissling, E., Hooiveld, M., Martínez‐Baz, I., Mazagatos, C., William, N., Vilcu, A., Kooijman, M. N., Ilić, M., Domegan, L. M., Machado, A., et al. (2021) · doi:10.31219/osf.io/3nhps · Cited by 2
Protection of Homologous and Heterologous Vaccine Boosters Against COVID-19 in SingaporePreprint
Tan, S. H. X., Pung, R., Wang, L., Lye, D. C., Ong, B. K. C., Cook, A. R., & Tan, K. B. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.3995101 · Cited by 2
Κοντοπούλου, Κ., Nakas, C. T., & Papazisis, G. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.3989286 · Cited by 2
Vaccine Effectiveness Against COVID-19 Infection Among 12 to 18 year olds in SingaporePreprint
Chiew, C. J., Premikha, M., Wei, W. E., Ong, B. K. C., Lye, D. C., Lee, V. J., & Tan, K. B. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3996796 · Cited by 2
Breakthrough COVID-19 Infections: What Are They and What Do They Look Like?
Elicker, B. M. (2022) · Radiology Cardiothoracic Imaging · doi:10.1148/ryct.210301 · Cited by 2
Novikov, M., Hasanpourghadi, M., Ambrose, R., Chekaoui, A., Newman, D., Giles‐Davis, W., Xiang, Z., Zhou, X., & Ertl, H. C. J. (2022) · SSRN Electronic Journal · doi:10.1101/2022.02.23.481620 · Cited by 1
Castillo, M. S., Khaoua, H., & Courtejoie, N. (2022) · medRxiv · doi:10.1101/2022.02.17.22270791 · Cited by 2
Wang, F.-Z., Huang, B., Lv, H., Feng, L., Ren, W., Wang, X., Tang, L., Liu, Q., Wu, D., Zheng, H., et al. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4065610 · Cited by 2
SARS-CoV-2 vaccine effectiveness and breakthrough infections in maintenance dialysis patientsPreprint
Manley, H. J., Aweh, G. N., Hsu, C. M., Weiner, D. E., Miskulin, D. C., Harford, A., Johnson, D. S., & Lacson, E. K., Jr. (2021) · medRxiv · doi:10.1101/2021.12.20.21268124 · Cited by 2
Tartof, S. Y., Slezak, J. M., Puzniak, L., Hong, V. X., Xie, F., Ackerson, B. K., Valluri, S. R., Jódar, L., & McLaughlin, J. M. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4150500 · Cited by 2
Self-citationLind, M. L., Copin, R., McCarthy, S., Coppi, A. C., Warner, F., Ferguson, D. J. P., Duckwall, C., Borg, R., Muenker, M. C., Overton, J. D., et al. (2022) · medRxiv · doi:10.1101/2022.08.25.22278443 · Cited by 2
Raponi, S., Durazzi, F., Derus, N. R., Giampieri, E., Miglio, R., Castellani, G., Sala, C., & with the Bologna MODELS4COVID Study Group (2023) · medRxiv · doi:10.1101/2023.07.12.23292559 · Cited by 2
Colonialism, Treatments, and Vaccinations
Blume, A. W. (2022) · International and cultural psychology/International and cultural psychology series · doi:10.1007/978-3-030-92825-4_7 · Cited by 1
Disease Severity in Vaccinated Adults Hospitalized with Breakthrough COVID-19
Finn, A., Selvaraj, V., Jindal, A., Tanzer, J. R., Lal, A., & Dapaah-Afriyie, K. (2022) · Hospital Topics · doi:10.1080/00185868.2022.2118093 · Cited by 1
Frequency of SARS-CoV-2 variants identified by real-time PCR in the AUNA healthcare network, Peru
Ortiz-Gómez, T., Gómez, A. C., Chuima, B., Zevallos, A., Ocampo, K., Torres, D., & Pinto, J. A. (2024) · Frontiers in Public Health · doi:10.3389/fpubh.2023.1244662 · Cited by 1
Yumiya, Y., Kawanishi, K., Chimed‐Ochir, O., Kishita, E., Sugiyama, A., Tanaka, J., & Kubo, T. (2024) · PLOS Global Public Health · doi:10.1371/journal.pgph.0003071 · Cited by 1
Rane, M. S., Shen, Y., Robertson, M. K., Penrose, K., Srivastava, A., Puzniak, L., Allen, K. E., Porter, T. M., Kulkarni, S., You, W., et al. (2024) · American Journal of Epidemiology · doi:10.1093/aje/kwae209 · Cited by 3
Cortier, T., Gilboa, M., Layan, M., Joseph, G., Meltzer, L., Amit, S., Rubin, C., Lustig, Y., Alroy‐Preis, S., Kreiss, Y., et al. (2025) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiaf001 · Cited by 2
He, A. W. J., Yuan, R., & Chan, S. C. S. (2025) · Vaccine · doi:10.1016/j.vaccine.2025.127308 · Cited by 1
A 20-month longitudinal study to evaluate humoral and cellular immunity after COVID-19 vaccines
Sobrinho, W. B. S., Salgado, B. B., Barbosa, A. R. C., Passos, V. A., Vieira, L. P., do Nascimento, L. D., Lalwani, J. D. B., Lalwani, P. J., & Nogueira, P. A. (2025) · Memórias do Instituto Oswaldo Cruz · doi:10.1590/0074-02760240193 · Cited by 1
Feng, Y., Wong, K. C.-Y., Tsui, W.-K., Zhang, R., Xiang, Y., & So, H. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26136441 · Cited by 1
Caetano, B. L. L., Pinto, P. B. A., Pacheco, A. R., Lage, A. R., Pereira, A., Nascimento, A. V. P., Machado, T. R., Paulino, A., Medeiros, T. L., Fernandes-Siqueira, L. O., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1603612 · Cited by 1
Yeganeh, A., Kalantar, E., Ghaffari, A., Keramatinia, A., & Yeganeh, F. (2025) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2025.2560063 · Cited by 1
Papadopoulos, I., Diep, A. N., Schyns, J., Gourzonès, C., Minner, F., Bonhomme, G., Paridans, M., Gillain, N., Husson, E., Garigliany, M., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1619631 · Cited by 1
Nazar, W., Romantowski, J., Nazar, G., Niedoszytko, M., & Daniłowicz‐Szymanowicz, L. (2025) · BMC Infectious Diseases · doi:10.1186/s12879-025-12023-w · Cited by 1
Hazan, A., Saperi, A. A., Zulkifli, N., MatRahim, N., Tiong, V., Lee, H.-Y., & AbuBakar, S. (2025) · Scientific Reports · doi:10.1038/s41598-025-28250-9 · Cited by 1
Bukke, S. P. N., Prajapati, S., Yadav, S., Thalluri, C., Chettupalli, A. K., Onohuean, H., Yahaya, U.-K. H., Goruntla, N., Janapati, Y. K., Shogar, A. E., et al. (2026) · Vaccine X · doi:10.1016/j.jvacx.2025.100777 · Cited by 1
Mitura, K. M., Celiński, D., Bielan, O., Snarska, J., & Szajda, S. D. (2026) · Frontiers in Public Health · doi:10.3389/fpubh.2026.1747666 · Cited by 1
Developing COVID-19 vaccine policy in increments
Saag, M. S. (2021) · The Lancet · doi:10.1016/s0140-6736(21)02242-x · Cited by 1
Chongloi, H. (2022) · International Journal of Human Rights in Healthcare · doi:10.1108/ijhrh-07-2022-0070 · Cited by 1
A genetically engineered, stem-cell-derived cellular vaccine
Cooper, A., Sidaway, A., Chandrashekar, A., Latta, E., Chakraborty, K., Yu, J., McMahan, K., Giffin, V. M., Manickam, C., Kroll, K. W., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100843 · Cited by 1
DeZure, C. P. (2023) · Pediatric Annals · doi:10.3928/19382359-20221114-02 · Cited by 1
Takeshita, Y., To, Y., Kurosawa, Y., Kinouchi, T., Tsuya, K., Tada, Y., & Tsushima, K. (2023) · ImmunoHorizons · doi:10.4049/immunohorizons.2200093 · Cited by 1
Singla, A., Dadario, N. B., Singla, A., Greenberg, P., Yan, R., Nanda, A., Boison, D., Malhotra, R., Patel, S., Nipun, S., et al. (2023) · PLoS ONE · doi:10.1371/journal.pone.0274243 · Cited by 1
George, T. K., Nair, N. P., Singh, A. K., Kumar, A., Roy, A. D., Mohan, V. N., & Kang, G. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.04.062 · Cited by 1
Impact of vaccination against SARS-CoV-2 on the incidence of infection in school settings
Herrero-Diez, M. T., Salado-Valdivieso, M. I., Carbajal-Domínguez, S., Allué-Tango, M., Villa-Caballero, J. C., & Berbel, C. (2023) · Vacunas (English Edition) · doi:10.1016/j.vacune.2023.06.002 · Cited by 1
Metadata
- Authors
- Tartof, S. Y., Slezak, J. M., Fischer, H., Hong, V., Ackerson, B. K., Ranasinghe, O. N., Frankland, T. B., Ogun, O. A., Zamparo, J. M., Gray, S., Valluri, S. R., Pan, K., Angulo, F. J., Jodar, L., & McLaughlin, J. M.
- Affiliations
- Kaiser Permanente (US)
- Pfizer (United States) (US)
- Corresponding author
- Tartof, Sara Y
- ORCID
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2021-10
- Volume
- 398
- Issue
- 10309
- Pages
- 1407-1416
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- PMC
- PMC8489881
- OpenAlex
- W3202826390
- Cited by
- 1,167
- References
- 37
- Citations by year
- 2026: 33 · 2025: 70 · 2024: 116 · 2023: 257 · 2022: 583 · 2021: 108
- FWCI
- 84.33
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- The Lancet (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Pfizer Inc Boulder
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Physical Sciences › Mathematics › Modeling and Simulation › COVID-19 epidemiological studies
- Keywords
- BNT162b2, COVID-19 vaccines, mRNA vaccines, vaccine effectiveness, COVID-19 pandemic, COVID-19 hospitalization, Delta variant, waning immunity, integrated health system, Kaiser Permanente, time since vaccination, SARS-CoV-2 sequencing
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, BNT162 Vaccine, Adolescent, Adult, Aged, Aged, 80 and over, Child, Female, Hospitalization, Humans, Male, Middle Aged, Organizations, Retrospective Studies, RNA, Messenger, Time Factors, United States, Vaccination, Delivery of Health Care, Integrated
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
